• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by NeuroOne Medical Technologies Corporation

    1/11/24 1:04:48 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care
    Get the next $NMTC alert in real time by email
    SC 13G 1 nmtc.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    NeuroOne Medical Technologies Corporation

    (Name of Issuer)

     

     

    Common Stock, par value $0.001

    (Title of Class of Securities)

     

     

    64130M209

    (CUSIP Number)

     

     

    December 28, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 64130M209

     

    1.Names of Reporting Persons.

    Laurence W. Lytton

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization USA

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 1,304,102

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 1,304,102
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,304,102

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.2%

     

    12. Type of Reporting Person (See Instructions) IN

     

     

     2 
    CUSIP No. 64130M209

    Item 1.

     

    (a)Name of Issuer

    NeuroOne Medical Technologies Corporation

     

    (b)Address of Issuer's Principal Executive Offices

    7599 Anagram Dr., Eden Prairie, MN 55344

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Laurence W. Lytton

    (b)The principal business office of the Filers is located at:

    467 Central Park West
    New York, NY 10025

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to shares of Common Stock, par value $0.001 of the Issuer (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 64130M209
     3 
    CUSIP No. 64130M209
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page.

     

    The percentages reported in this Schedule 13G are based on 25,311,404 shares of Common Stock outstanding as of January 3, 2024, as reported in the Prospectus Supplement filed by the Issuer on January 5, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 11, 2024

     

     

    /s/ Laurence W. LyttonI

    Laurence W. Lytton

     

     

     

    Get the next $NMTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NMTC

    DatePrice TargetRatingAnalyst
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    3/29/2022$6.00 → $2.00Buy → Hold
    Craig Hallum
    12/3/2021$5.75Buy
    Alliance Global Partners
    11/15/2021$6.00Buy
    Craig-Hallum
    More analyst ratings

    $NMTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

      SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      11/26/24 8:42:10 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

      SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      11/14/24 3:41:01 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by NeuroOne Medical Technologies Corporation

      SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      2/14/24 4:51:41 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

      EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

      6/3/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025

      EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025. Dave Rosa, President and CEO of NeuroOne will be meeting with investors during the two-day event that will feature informative panel discussions, keynote talks and corporate presentations on medical devices, imaging technologies, diagnostics, AI/data analytics and digital

      5/29/25 1:05:36 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

      Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati

      5/13/25 7:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mcclurg Ronald W. bought $100,000 worth of shares (200,000 units at $0.50), increasing direct ownership by 82% to 444,117 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      4/7/25 4:47:21 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • CEO and President Rosa David A bought $50,000 worth of shares (100,000 units at $0.50), increasing direct ownership by 9% to 1,161,289 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      4/7/25 4:38:47 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Volker Christopher bought $105,000 worth of shares (75,000 units at $1.40) (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      12/26/23 4:08:51 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Numerical Tech with a new price target

      Ladenburg Thalmann initiated coverage of Numerical Tech with a rating of Buy and set a new price target of $1.45

      5/5/25 8:32:14 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Numerical Tech downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously

      3/29/22 8:37:16 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Alliance Global Partners initiated coverage on NeuroOne Medical Tech with a new price target

      Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75

      12/3/21 9:56:11 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    SEC Filings

    See more

    $NMTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by NeuroOne Medical Technologies Corporation

      SCHEDULE 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

      5/15/25 3:49:33 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

      5/13/25 8:15:21 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by NeuroOne Medical Technologies Corporation

      10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

      5/13/25 8:01:14 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by General Counsel Johns Emily J.

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      6/3/25 3:45:04 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Johns Emily J.

      3 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      6/3/25 3:38:03 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • Business Development Director Christianson Mark sold $5,596 worth of shares (8,981 units at $0.62), decreasing direct ownership by 3% to 271,491 units (SEC Form 4)

      4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

      5/23/25 4:03:34 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Financials

    Live finance-specific insights

    See more
    • NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%

      Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025. Recent Company Highlights Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablati

      5/13/25 7:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time

      EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f

      5/1/25 9:55:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update

      Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024. First Quarter Financial Highlights Product revenue increased 235% to $3.3 million in the first quarter of fiscal year 2025, compared to $1.0 million in the first quarter of fiscal

      2/12/25 8:00:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care

    $NMTC
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

      EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

      6/3/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

      Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol

      5/12/25 8:30:00 AM ET
      $NMTC
      Medical/Dental Instruments
      Health Care
    • NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at

      11/14/23 5:15:00 PM ET
      $NMTC
      Medical/Dental Instruments
      Health Care